PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [

DTC PET TR1402 TSHR thyroid

Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
08 Jul 2024
Historique:
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: aheadofprint

Résumé

Thyroid cancer is the most common endocrine cancer, with differentiated thyroid cancers (DTCs) accounting for 95% of diagnoses. While most DTC patients are diagnosed and treated with radioiodine (RAI), up to 20% of DTC patients become RAI refractory (RAI-R). RAI-R patients have significantly reduced survival rates compared to patients who remain RAI-avid. This study explores [

Identifiants

pubmed: 38976794
doi: 10.1021/acs.molpharmaceut.4c00224
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Grayson R Gimblet (GR)

Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.

Hailey A Houson (HA)

Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.

Jason Whitt (J)

Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.

Pratheek Reddy (P)

Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.

John Al Copland (JA)

Department of Cancer Biology, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, United States.

Saad S Kenderian (SS)

Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota 55905, United States.

Mariusz W Szkudlinski (MW)

Trophogen, Inc., Rockville, Maryland 20850, United States.

Renata Jaskula-Sztul (R)

Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.

Suzanne E Lapi (SE)

Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.

Classifications MeSH